EL7.AI
Mergers & AcquisitionsMedium•19 November 2026•
2 min read

Zoetis Offers to Divest Australian Assets as Review of Genome Business Sale Runs Late

Key Facts

1Zoetis offered to divest certain assets in Australia to help secure regulatory clearance, and Neogen expects the review to conclude in early 2027.
2Neogen announced the definitive agreement to sell its global genomics business to Zoetis on March 2, 2026.
3The Australian commission referred the deal to a Phase 2 review on July 17, 2026.
4The agreement was valued at $160.0 million.
5The genomics business generated sales of about $90 million in fiscal 2025.

Neogen said in a filing dated November 4, 2026, that Zoetis offered to divest certain assets in Australia to help secure regulatory clearance for the sale of Neogen’s global genomics business. The company added that it expects the regulatory review to conclude in early 2027. The filing places the offer within the ongoing deal review, without identifying the assets involved or saying that the divestiture would guarantee approval. The parties announced the definitive agreement on March 2, 2026. The deal is subject to customary closing conditions and regulatory approvals, and the parties are cooperating with regulators in Australia and New Zealand.

The Australian Competition and Consumer Commission and the New Zealand Commerce Commission are conducting ongoing reviews of the deal, according to Neogen. On July 17, 2026, the Australian commission decided to subject the agreement to a Phase 2 review, an in-depth assessment. The commission said the deal could substantially lessen competition. The move to this phase reflects scrutiny of the effect of combining the two companies’ businesses, while regulatory clearance is still required to complete the sale. Neogen’s filing did not specify a separate date for a final decision by either authority.

The Australian commission’s concerns focus on the livestock genomic testing services market. It said the two companies provide these services for beef cattle, dairy cattle and sheep in Australia, and that the deal would combine the country’s two largest suppliers of genomic testing services for cattle. The commission found that competitive alternatives are limited and barriers to entering and expanding in the market are significant. It is also examining whether Zoetis gaining greater scale and scope of Australian cattle and sheep genetic data through the deal would affect competition. These issues define the areas of the review that Neogen said the parties are addressing with regulators.

The agreement concerns the sale of Neogen’s global genomics business and does not include the sale of the entire company. Neogen valued the definitive agreement at $160.0 million. The genomics business generated sales of about $90 million in fiscal 2025, according to the company’s announcement. This puts the deal in the context of an operating business with reported revenue, while completion of the sale remains subject to customary conditions and regulatory approvals. The Australian and New Zealand reviews remain part of the regulatory process that Neogen expects to conclude in early 2027.

Open on chart